Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers

Kimford J. Meador, D. W. Loring, V. J. Vahle, Patty G Ray, M. A. Werz, A. J. Fessler, P. Ogrocki, M. R. Schoenberg, J. M. Miller, R. P. Kustra

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background: The relative cognitive and behavioral effects of lamotrigine (LTG) and topiramate (TPM) are unclear. Methods: The authors directly compared the cognitive and behavioral effects of LTG and TPM in 47 healthy adults using a double-blind, randomized crossover design with two 12-week treatment periods. During each treatment condition, subjects were titrated to receive either LTG or TPM at a target dose of 300 mg/day for each. Neuropsychological evaluation included 17 measures yielding 41 variables of cognitive function and subjective behavioral effects. Subjects were tested at the end of each antiepileptic drug (AED) treatment period and during two drug-free conditions (pretreatment baseline and 1 month following final AED withdrawal). Results: Direct comparison of the two AEDs revealed significantly better performance on 33 (80%) variables for LTG, but none for TPM. Even after adjustment for blood levels, performance was better on 19 (46%) variables for LTG, but none for TPM. Differences spanned both objective cognitive and subjective behavioral measures. Comparison of TPM to the non-drug average revealed significantly better performance for non-drug average on 36 (88%) variables, but none for TPM. Comparison of LTG to non-drug average revealed better performance on 7 (17%) variables for non-drug average and 4 (10%) variables for LTG. Conclusions: Lamotrigine produces significantly fewer untoward cognitive and behavioral effects compared to topiramate (TPM) at the dosages, titrations, and timeframes employed in this study. The dosages employed may not have been equivalent in efficacy. Future studies are needed to delineate the cognitive and behavioral effects of TPM at lower dosages.

Original languageEnglish (US)
Pages (from-to)2108-2114
Number of pages7
JournalNeurology
Volume64
Issue number12
DOIs
StatePublished - Jun 28 2005

Fingerprint

Healthy Volunteers
Anticonvulsants
topiramate
lamotrigine
Cross-Over Studies
Cognition
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Meador, K. J., Loring, D. W., Vahle, V. J., Ray, P. G., Werz, M. A., Fessler, A. J., ... Kustra, R. P. (2005). Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology, 64(12), 2108-2114. https://doi.org/10.1212/01.WNL.0000165994.46777.BE

Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. / Meador, Kimford J.; Loring, D. W.; Vahle, V. J.; Ray, Patty G; Werz, M. A.; Fessler, A. J.; Ogrocki, P.; Schoenberg, M. R.; Miller, J. M.; Kustra, R. P.

In: Neurology, Vol. 64, No. 12, 28.06.2005, p. 2108-2114.

Research output: Contribution to journalArticle

Meador, KJ, Loring, DW, Vahle, VJ, Ray, PG, Werz, MA, Fessler, AJ, Ogrocki, P, Schoenberg, MR, Miller, JM & Kustra, RP 2005, 'Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers', Neurology, vol. 64, no. 12, pp. 2108-2114. https://doi.org/10.1212/01.WNL.0000165994.46777.BE
Meador KJ, Loring DW, Vahle VJ, Ray PG, Werz MA, Fessler AJ et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology. 2005 Jun 28;64(12):2108-2114. https://doi.org/10.1212/01.WNL.0000165994.46777.BE
Meador, Kimford J. ; Loring, D. W. ; Vahle, V. J. ; Ray, Patty G ; Werz, M. A. ; Fessler, A. J. ; Ogrocki, P. ; Schoenberg, M. R. ; Miller, J. M. ; Kustra, R. P. / Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. In: Neurology. 2005 ; Vol. 64, No. 12. pp. 2108-2114.
@article{a402d5894b8c498096808d04231580fc,
title = "Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers",
abstract = "Background: The relative cognitive and behavioral effects of lamotrigine (LTG) and topiramate (TPM) are unclear. Methods: The authors directly compared the cognitive and behavioral effects of LTG and TPM in 47 healthy adults using a double-blind, randomized crossover design with two 12-week treatment periods. During each treatment condition, subjects were titrated to receive either LTG or TPM at a target dose of 300 mg/day for each. Neuropsychological evaluation included 17 measures yielding 41 variables of cognitive function and subjective behavioral effects. Subjects were tested at the end of each antiepileptic drug (AED) treatment period and during two drug-free conditions (pretreatment baseline and 1 month following final AED withdrawal). Results: Direct comparison of the two AEDs revealed significantly better performance on 33 (80{\%}) variables for LTG, but none for TPM. Even after adjustment for blood levels, performance was better on 19 (46{\%}) variables for LTG, but none for TPM. Differences spanned both objective cognitive and subjective behavioral measures. Comparison of TPM to the non-drug average revealed significantly better performance for non-drug average on 36 (88{\%}) variables, but none for TPM. Comparison of LTG to non-drug average revealed better performance on 7 (17{\%}) variables for non-drug average and 4 (10{\%}) variables for LTG. Conclusions: Lamotrigine produces significantly fewer untoward cognitive and behavioral effects compared to topiramate (TPM) at the dosages, titrations, and timeframes employed in this study. The dosages employed may not have been equivalent in efficacy. Future studies are needed to delineate the cognitive and behavioral effects of TPM at lower dosages.",
author = "Meador, {Kimford J.} and Loring, {D. W.} and Vahle, {V. J.} and Ray, {Patty G} and Werz, {M. A.} and Fessler, {A. J.} and P. Ogrocki and Schoenberg, {M. R.} and Miller, {J. M.} and Kustra, {R. P.}",
year = "2005",
month = "6",
day = "28",
doi = "10.1212/01.WNL.0000165994.46777.BE",
language = "English (US)",
volume = "64",
pages = "2108--2114",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers

AU - Meador, Kimford J.

AU - Loring, D. W.

AU - Vahle, V. J.

AU - Ray, Patty G

AU - Werz, M. A.

AU - Fessler, A. J.

AU - Ogrocki, P.

AU - Schoenberg, M. R.

AU - Miller, J. M.

AU - Kustra, R. P.

PY - 2005/6/28

Y1 - 2005/6/28

N2 - Background: The relative cognitive and behavioral effects of lamotrigine (LTG) and topiramate (TPM) are unclear. Methods: The authors directly compared the cognitive and behavioral effects of LTG and TPM in 47 healthy adults using a double-blind, randomized crossover design with two 12-week treatment periods. During each treatment condition, subjects were titrated to receive either LTG or TPM at a target dose of 300 mg/day for each. Neuropsychological evaluation included 17 measures yielding 41 variables of cognitive function and subjective behavioral effects. Subjects were tested at the end of each antiepileptic drug (AED) treatment period and during two drug-free conditions (pretreatment baseline and 1 month following final AED withdrawal). Results: Direct comparison of the two AEDs revealed significantly better performance on 33 (80%) variables for LTG, but none for TPM. Even after adjustment for blood levels, performance was better on 19 (46%) variables for LTG, but none for TPM. Differences spanned both objective cognitive and subjective behavioral measures. Comparison of TPM to the non-drug average revealed significantly better performance for non-drug average on 36 (88%) variables, but none for TPM. Comparison of LTG to non-drug average revealed better performance on 7 (17%) variables for non-drug average and 4 (10%) variables for LTG. Conclusions: Lamotrigine produces significantly fewer untoward cognitive and behavioral effects compared to topiramate (TPM) at the dosages, titrations, and timeframes employed in this study. The dosages employed may not have been equivalent in efficacy. Future studies are needed to delineate the cognitive and behavioral effects of TPM at lower dosages.

AB - Background: The relative cognitive and behavioral effects of lamotrigine (LTG) and topiramate (TPM) are unclear. Methods: The authors directly compared the cognitive and behavioral effects of LTG and TPM in 47 healthy adults using a double-blind, randomized crossover design with two 12-week treatment periods. During each treatment condition, subjects were titrated to receive either LTG or TPM at a target dose of 300 mg/day for each. Neuropsychological evaluation included 17 measures yielding 41 variables of cognitive function and subjective behavioral effects. Subjects were tested at the end of each antiepileptic drug (AED) treatment period and during two drug-free conditions (pretreatment baseline and 1 month following final AED withdrawal). Results: Direct comparison of the two AEDs revealed significantly better performance on 33 (80%) variables for LTG, but none for TPM. Even after adjustment for blood levels, performance was better on 19 (46%) variables for LTG, but none for TPM. Differences spanned both objective cognitive and subjective behavioral measures. Comparison of TPM to the non-drug average revealed significantly better performance for non-drug average on 36 (88%) variables, but none for TPM. Comparison of LTG to non-drug average revealed better performance on 7 (17%) variables for non-drug average and 4 (10%) variables for LTG. Conclusions: Lamotrigine produces significantly fewer untoward cognitive and behavioral effects compared to topiramate (TPM) at the dosages, titrations, and timeframes employed in this study. The dosages employed may not have been equivalent in efficacy. Future studies are needed to delineate the cognitive and behavioral effects of TPM at lower dosages.

UR - http://www.scopus.com/inward/record.url?scp=21144456722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144456722&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000165994.46777.BE

DO - 10.1212/01.WNL.0000165994.46777.BE

M3 - Article

C2 - 15985582

AN - SCOPUS:21144456722

VL - 64

SP - 2108

EP - 2114

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -